the heart of our mission to develop global medicines for incurable diseases.
A driving force to leap to the “Global Health Care Group Leading Improvement of Life Quality”
Yet, the needs for development of products for diseases with no proper therapeutic method and for development of conventional medicines with no problem are very high.
Hanall Bio Research Center is studying and developing new global bio medicines through Bio Better modified from conventional medicines and R&D of therapeutic antibody with new mechanism.
By using the amino acid transfer technology, we are developing anti-TNT Bio Better with improved stability, distribution rate in tissue, and medicinal effect as a therapeutic eye bath drop to cure dry eye that overcomes limitations of conventional protein medicines.
We are studying for novel antibodies with novel mechanism to target various severe autoimmune diseases.
Likewise, through the development of new global bio medicine, Hanall Biopharma will save patients from diseases and pain, and we will contribute to the export of technology and expansion of sales to become the best corporation of new bio medicine in the country.
The most significant characteristic of anticancer immuno-antibody is to bring continuous anticancer effect by raising an immune system of patient, and thus the anticancer immuno-antibody is being highlighted as the medicine to open the era of complete cure of cancer. Yet, there are not many patients reacting to anticancer immuno-antibodies in the market. Hanall is concentratinge on R&D of the future anticancer immuno-antibody.
To screening for promising antibody candidates, we use both phage display technology and hybridoma technology to select various antibody candidates. Based on effects, the final antibody candidates will be selected through the verification steps: stage 1 (in vitro assay), stage 2 (ex vivo assay), and stage 3 (in vivo assay).
Through the joint study with outside specialists and field experts, we analyze the distribution of target and ligand on immune cells patients and explore the characteristics of cancer cells and immune cells of the patients who do not react to conventional anticancer immuno-antibodies for development of biomarkers.
We explore not only the independent effects of selected antibody candidates but also other anticancer immuno-antibodies and anticancer medicines to reveal the optimal remedial effect from parallel use to bring hope to all patients in pain from cancers.
Depending on conditions and symptoms of each patient, types and quantities of essential nutrients shall vary. The Central Research Center of Hanall Biopharma is studying and developing medicines of intravenous nutrition therapy to maintain health of mankind as the followings.
Hanall Biopharma Co., Ltd. is studying and developing new advanced products modified from conventional products to easily adjust types and quantities of nutrients within infusion and IV injection for conditions of individuals.
For competitiveness not only in the domestic market but also in the global market, Hanall Biopharma Co., Ltd. is studying and developing distinctive new products by improving new injection containers and storage conditions.
For health of patients, Hanall Biopharma Co., Ltd. is studying and developing products with higher quality to be manufactured and distributed.